Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 6c ; Offers Guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q1 EPS of $0.21, $0.06 better than the analyst estimate of $0.15. Revenue for the quarter came in at $695 million versus the consensus estimate of $726.49 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2025 EPS of $0.60-$0.70, versus the consensus of $0.68. Amneal Pharmaceuticals sees FY2025 revenue of $3-3.1 billion, versus the consensus of $3.03 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• Edgewell stock surges on report of rejected takeover bid